Foundation Medicine, Inc.

Bio-Rad Laboratories, Inc.

Integrated Dna Technologies, Inc.

Bio-Rad Haifa Ltd.

Genentech, Inc.

The General Hospital Corporation

Roche Finance Ltd

Sequenom, Inc.

Doron Lipson

Philip James Stephens

Roman Yelensky

Ariel Lipson

Ariel Notcovich

Sean R Downing

Alexander Nevin Parker

Geoffrey Alan Otto

Matthew J Hawryluk

Vincent A Miller

Jeffrey S Ross

Boaz Ran

Stephen Geoffrey Lipson

Maureen T Cronin

Mikhail G Shapiro

Mirna Jarosz

Siraj Mahamed Ali

Mima Jarosz

Mark Aaron Behlke

Stanley N Lapidus

Daniel Arie Haber

J William Efcavitch

Shay Nimri

Jie He

Garrett Michael Frampton

Gary Palmer

Shai Nimri

Zachary Zwirko

John J Barich

John Robert Havens

Ran Boaz

Alon Herschhorn

Joel Robert Greenbowe

Frank Soo Juhn

Yaakov Levie

Shyamala Maheswaran

David T Ting

David Fabrizio

John F Thompson

David Shames

Erica Beth Schleifman

Michelle Nahas

Travis Clark

Mark Kennedy

Shan Zhong

Daniel Lieber

Craig Anthony Cummings

Yan Li

Sarah Margaret Shagan

David Tsai Ting

Patrice M Milos

Stanley Letovsky

Scott Daniel Rose

Novel fusion molecules and uses are disclosed.

Fusion molecules and uses thereof

Methods and compositions for treating cholangiocarcinoma.

Methods of treating cholangiocarcinoma

Novel RET fusion molecules and uses are disclosed.

KIF5B-RET fusion molecules and uses thereof

A method of analyzing a tumor sample comprising:

Optimization of multigene analysis of tumor samples

Novel mutant ESR1 molecules and uses are disclosed.

Estrogen receptor mutations and uses thereof

Methods of evaluating or providing a clonal profile of a subject interval, e.g., a subgenomic interval, or an expressed subgenomic interval (or of a cell containing the same), in a subject, are disclosed.

Multigene analysis of tumor samples

The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

Therapeutic and diagnostic methods for cancer

Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.

NTRK1 fusion molecules and uses thereof

The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tof the resultant oligonucleotide composition.

T-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection

Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.

Biomarkers of cancer

Growing community of inventors

Chestnut Hill, MA, United States of America

Doron Lipson